MedTrace Logo

Trental & Vitamin E for Radiation-Induced Fibrosis

NCT00583700 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2013-01-29

Study results available
· View outcomes & findings →

Summary

This study seeks to determine if a combination of Trental and Vitamin E prevents the development of radiation fibrosis in women treated with radiation for the definitive management of their breast cancer.

Conditions

Interventions

DRUG

Pentoxifylline

Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.

DRUG

Vitamin E

Vitamin E (Over-the-counter) 400 I.U. once daily

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Principal Investigators

  • Geraldine Jacobson, MD MPH · department of radiation oncology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2010-05-31
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00583700 on ClinicalTrials.gov